PV Reporter

01/12/2026

New targeted treatment offers hope for people with myelofibrosis

https://www.scimex.org/newsfeed/new-targeted-treatment-offers-hope-for-people-with-myelofibrosis

01/06/2026

Big News for the Myelofibrosis Community! 📣

For a long time, many Myelofibrosis patients in the early stages have been told to "watch and wait." But a new 2025 study suggests that "acting early" might be the better path.

The study found that using Interferon early on can help reduce bone marrow scarring and lower the "burden" of the disease. This is a huge win for those looking for proactive ways to manage their health!

Check out the article to learn more about these findings:
👉 https://www.pvreporter.com/interferon-for-myelofibrosis-2025-study-challenges-watch-and-wait/

Early interferon treatment in pre-fibrotic myelofibrosis may slow disease progression, reduce fibrosis, and challenge the long-standing watch-and-wait approach.

01/05/2026

📰 Alright, now that the holidays are over it's time for a good news update:

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

https://financialpost.com/pmn/business-wire-news-releases-pmn/takeda-and-protagonist-announce-submission-of-new-drug-application-nda-for-rusfertide-for-treatment-of-polycythemia-vera-pv

01/01/2026

Wishing you a healthy, Happy New Year!

12/23/2025

Warm wishes for a joyful holiday season filled with love, laughter, and cherished moments. Happy Holidays!

12/19/2025

Teenage me wanted to shred solos and "make bad decisions." 🎸 Life had other plans. It skipped the tour bus and put me on a different stage.

Now I’m a Patient Advocate, Educator, and occasional Myth Buster. 🎤 Is it what I expected? No. Is it better than a burnt-out music career? Hell yeah!

This work matters, and I’m just getting tuned up. See you in 2026 to continue the mission Together.

Enjoy the holidays and keep shredding. 🤘

12/12/2025

👍Ajax Therapeutics Receives Orphan Drug Designation from the U.S. FDA for AJ1-11095 for the Treatment of Myelofibrosis

https://www.ajaxtherapeutics.com/press-release/ajax-therapeutics-receives-orphan-drug-designation-from-the-u-s-fda-for-aj1-11095-for-the-treatment-of-myelofibrosis/

12/09/2025

Incyte INCY announced that the FDA has granted the Breakthrough Therapy designation to its investigational, first-in-class, mutCALR-targeted monoclonal antibody, INCA033989, to treat patients with essential thrombocythemia (ET).

INCY secures FDA Breakthrough Therapy status for INCA033989 after early data show rapid and sustained platelet normalization in essential thrombocythemia patients.

12/08/2025

12/08/2025

ASH 2025: A turning point for MPNs? 🩸

​I’ve had a press pass for this conference for many years, and it's truly an honor, but I’ve never seen a pipeline this crowded. Even fighting off a cold, I made sure to visit the posters that mattered and had excellent meetings with industry partners!

📰 One of ​the most exciting takeaways: There are now at least 5 companies actively exploring new 2nd generation JAK inhibitors. This kind of investment in our disease space is exactly what we’ve been waiting for.

Stay tuned...​more updates to follow on the PV Reporter website.

12/07/2025

Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025

https://investor.incyte.com/news-releases/news-release-details/incyte-announces-new-positive-data-inca033989-its-first-class/

See more news from Incyte in the comments.

12/02/2025

Polycythemia Vera Update: Is NLR the New Biomarker to Watch? 🩸

​New research highlights the Neutrophil-to-Lymphocyte Ratio (NLR) as a valuable tool for tracking treatment response in PV.

Here are the key takeaways from the study:

​Simple & Free: NLR is calculated from a standard Complete Blood Count (CBC), meaning no extra cost or testing is required.

​Treatment Impact:
​Phlebotomy: Tend to increase NLR.
​Hydroxyurea: Keeps NLR stable.
​Interferons: Uniquely effective at reducing NLR.

​Why It Matters: Lowering NLR was correlated with deeper molecular responses (reduction in JAK2 mutation burden) and better patient outcomes.

Joseph Scandura, MD, PhD, Weill Cornell Medicine, New York, NY, discusses the potential use of the neutrophil-to-lymphocyte ratio (NLR) as a dynamic biomarke...